Fig. 2From: Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptinea Cumulative incidence of valvular heart disease with death as a competing risk among bromocriptine-treated patients and matched controls. b Cumulative incidence of competing risk of death among bromocriptine-treated patients and matched controlsBack to article page